This article is for educational and research purposes only. Nothing here constitutes medical advice. Consult a licensed healthcare provider before using any peptide.
What Is SS-31 (Elamipretide)?
SS-31, also known as elamipretide and by its trade name Stegazo (bendavia was its earlier clinical name), is a synthetic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) that selectively targets the inner mitochondrial membrane. Developed by Dr. Hazel Szeto at Weill Cornell Medical College (hence the "SS" designation — Szeto-Schiller), it belongs to a class of mitochondria-targeted peptides designed to restore mitochondrial function at the organelle level.
What makes SS-31 unique is its mechanism: rather than acting on cell surface receptors like most peptides, it concentrates 1,000-5,000-fold within mitochondria, where it interacts directly with cardiolipin — a phospholipid unique to the inner mitochondrial membrane that is essential for electron transport chain function.
Mechanism of Action
SS-31's mechanism is centered on mitochondrial inner membrane stabilization:
- Cardiolipin binding: SS-31 binds to cardiolipin, stabilizing the interaction between cardiolipin and cytochrome c. This restores optimal electron transfer through Complex III and Complex IV, reducing electron leak and reactive oxygen species (ROS) production. Cardiolipin becomes oxidized and dysfunctional with aging, making this a targeted intervention for age-related mitochondrial decline.
- ATP production: By improving electron transport chain efficiency, SS-31 increases ATP production while reducing the bioenergetic waste associated with mitochondrial dysfunction.
- ROS reduction: Unlike antioxidants that scavenge free radicals after they form, SS-31 reduces ROS production at the source by preventing electron leak from the respiratory chain.
- Mitochondrial cristae stabilization: Electron microscopy studies show SS-31 treatment restores the normal architecture of mitochondrial cristae (inner membrane folds), which become disorganized with age and disease.
Clinical and Preclinical Evidence
Preclinical studies in aged mice demonstrated that SS-31 reversed age-related mitochondrial dysfunction in skeletal muscle, restored exercise capacity, improved cardiac function, and reversed kidney aging markers. Aged mice treated with SS-31 showed rejuvenated mitochondrial cristae architecture and restored proteome profiles to levels comparable to young animals within hours of treatment.
Clinical trials have focused primarily on heart failure. The PROGRESS-HF trial evaluated elamipretide in patients with heart failure with reduced ejection fraction (HFrEF). While initial results showed improvements in cardiac volumes and biomarkers, the Phase III PROGRESS trial did not meet its primary endpoint. Stealth BioTherapeutics (now Larimar Therapeutics) has also pursued trials for Barth syndrome — a rare mitochondrial disease — with positive results leading to the first FDA approval consideration for a mitochondria-targeted therapy.
Additional studies have explored SS-31 for age-related macular degeneration, acute kidney injury, and skeletal muscle aging, with promising preclinical data in each area.
Dosing and Administration
- Clinical trial doses: 4 mg/day via subcutaneous injection in most human trials
- Research doses: Vary widely in preclinical settings; human extrapolation from animal studies is complex
- Route: Subcutaneous injection; the peptide rapidly concentrates in mitochondria after systemic administration
The Bottom Line
SS-31/elamipretide represents a genuinely novel approach to mitochondrial medicine — targeting the structural and functional integrity of the inner mitochondrial membrane rather than acting on receptors or signaling pathways. The preclinical evidence for reversing age-related mitochondrial dysfunction is compelling. Clinical translation has been challenging, with mixed results in heart failure trials, but the Barth syndrome program and ongoing age-related studies continue to advance. It remains an investigational drug not approved for general use.